The group’s principle activities include discovering, developing and commercializing targeted immunotherapeutic agents for the treatment of cancer, viral infections, and autoimmune diseases. The group’s products include STAR™ -Ck , and a monoclonal antibody which prevents and treats staphylococcal infections in premature neonates. The group operates from United States.
